All Stories

  1. The A to Z of Peroral Endoscopic Myotomy
  2. The safety and efficacy of endoscopic approaches for the management of Zenker’s diverticulum: a multicentre retrospective study
  3. A disease-associated gene desert directs macrophage inflammation through ETS2
  4. Endoscopic suturing and clipping devices for defects in the GI tract
  5. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
  6. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
  7. Role of oesophageal balloon cryoablation in combination with personalised immunotherapy to achieve luminal control in metastatic oesophageal cancer: a case report
  8. The endoscopic management of oesophageal strictures
  9. Metabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes?
  10. Peroral endoscopic myotomy for the management of symptomatic cricopharyngeal bar (C-POEM): a case series and video demonstration
  11. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
  12. Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients
  13. Symptomatic duodenal metastasis from a small cell lung cancer primary: a rare case
  14. Metabolic and Bariatric Endoscopy: A Mini-Review
  15. Management of a large percutaneous endoscopic gastrostomy tube-associated gastric ulcer with endoscopic suturing
  16. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
  17. Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease
  18. Phenome-Wide Association Study of Drugs and Co-morbidities Associated with Gastrointestinal Dysfunction in Systemic Sclerosis
  19. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)
  20. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a pr...
  21. Between progress and changing times: The journey of UEG Education Committee's chair
  22. Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID ‐19 pandemic: the PREPARE‐IBD multicentre cohort study
  23. Blood and guts
  24. Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease
  25. Diagnostic Performance of Magnetic Resonance Enterography Disease Activity Indices Compared with a Histological Reference Standard for Adult Terminal Ileal Crohn’s Disease: Experience from the METRIC Trial
  26. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
  27. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
  28. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients
  29. The Relationship Between Mucosal Microbiota, Colitis, and Systemic Inflammation in Chronic Granulomatous Disorder
  30. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
  31. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
  32. Benefits of Structured Pediatric to Adult Transition in Inflammatory Bowel Disease
  33. Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients
  34. The relationship between mucosal microbiota, colitis and systemic inflammation in Chronic Granulomatous Disorder
  35. Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis
  36. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
  37. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study
  38. Endoscopy during the peak of COVID-19 pandemic: impact on activity and financial implications for a tertiary referral center in London
  39. Editorial: fatigue—difficult to assess and difficult to treat
  40. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
  41. UEG Guidelines framework to guide clinical practice
  42. Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic
  43. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
  44. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
  45. The cost-effectiveness of radiofrequency ablation for treating patients with gastric antral vascular ectasia refractory to first line endoscopic therapy
  46. UEG Education—building on success
  47. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
  48. Diagnosis and management of bile acid diarrhoea: a survey of UK expert opinion and practice
  49. Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn’s disease patients: the METRIC diagnostic accuracy study
  50. IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn’s and Colitis
  51. Chronic Granulomatous Disorder–Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level
  52. Editorial: combination immunosuppressive therapy to treat Crohn’s disease - ready for all age groups?
  53. Radiological findings in gastrointestinal scleroderma
  54. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
  55. Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis
  56. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
  57. Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia
  58. In memory of Dr Tomer Adar
  59. A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population
  60. Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease
  61. Magnetic resonance enterography, small bowel ultrasound and colonoscopy to diagnose and stage Crohn’s disease: patient acceptability and perceived burden
  62. Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial
  63. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis
  64. Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine
  65. There is a need for new systemic sclerosis subset criteria. A content analytic approach
  66. PTH-041 Definitive management of a very rare cause of significant acute upper gastrointestinal bleeding: gastric lipoma resected by hybrid endoscopic submucosal dissection
  67. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care
  68. Small bowel obstruction caused by a migrated Obalon gastric bariatric balloon: nonsurgical management by antegrade double-balloon panenteroscopy
  69. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial
  70. The role of dietary supplements in inflammatory bowel disease
  71. Small and Large Intestinal Involvement and Nutritional Issues
  72. Gallstone mimicry: a rare cause of abdominal pain
  73. Gastrointestinal manifestations of systemic sclerosis
  74. The ABC of E-learning: Utilizing E-learning resources for training and research in gastroenterology
  75. Elevated liver enzymes in inflammatory bowel disease
  76. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis
  77. P.14.3 CORRELATION BETWEEN CLINICAL RESPONSE AND ANEMIA RESOLUTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNF INHIBITORS
  78. Endoscopic resection of a giant ileal inflammatory fibroid polyp by retrograde double-balloon enteroscopy
  79. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease
  80. Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs
  81. OP-16 DIETARY INTERVENTION USING THE LOW FODMAP DIET VERSUS THE “MILK, EGG, WHEAT AND SOYA FREE” DIET FOR TREATMENT OF FUNCTIONAL GUT DISORDERS A SINGLE CENTRE EXPERIENCE
  82. Gastro-oesophageal dismotility measurements in scleroderma-associated interstitial lung disease: Correlation with respiratory and reflux symptoms
  83. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis
  84. Intractable diarrhoea despite immune reconstitution in an HIV positive man
  85. UEG E‐learning: The future has arrived
  86. Indurated plaques on the penis
  87. Gut symptoms in diabetics correlate with components of the rectoanal inhibitory reflex, but not with pudendal nerve motor latencies or systemic autonomic neuropathy
  88. PTH-056 Trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis
  89. Hepatic portal venous gas and portal venous thrombosis following colonoscopy in a patient with terminal ileal Crohn's disease
  90. Irritable bowel syndrome
  91. Travel health and pretravel preparation in the patient with inflammatory bowel disease
  92. Sa1264 A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centred Pilot Study to Assess the Symptomatic Treatment of Ulcerative Colitis With Cannabidiol
  93. A rare cause of abdominal pain, diarrhoea and GI bleeding
  94. UEG Education: time to shape the future
  95. METRIC (MREnterography or ulTRasound in Crohn’s disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in tho...
  96. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis
  97. OC-055 Ibd Passport-developing An Evidence-based Internet Travel Resource For Inflammatory Bowel Disease: A Report Of The Initial Stages Of Implementation
  98. PTU-092 Patient And Professionals Perceptions Of Travel Behaviour In Inflammatory Bowel Disease
  99. PWE-115 Patients Continue To Travel Abroad Despite Recently Active Disease And Travel Concerns: Results Of A Single Centre Study In Inflammatory Bowel Disease And Travel
  100. PWE-183 Preliminary Significant Findings From A Randomised Control Trial Of Posterior Tibial Nerve Stimulation In Systemic Sclerosis Associated Faecal Incontinence
  101. P574 A recent flare of disease does not prohibit travel: early results of a single centre study in inflammatory bowel disease and travel
  102. P553 A single-centre pilot study examining internet use for health related information among patients with inflammatory bowel disease
  103. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management
  104. Using an ‘action set’ for the management of acute upper gastrointestinal bleeding
  105. Bloody Diarrhoea
  106. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy
  107. PTH-132 Iron Deficiency Anaemia Nurse Led Clinic: Audit of 1st Year
  108. P57 Comparative Cost-Effectiveness of IGRA to Detect Latent TB Infection in UK Inflammatory Bowel Disease Patients Initiating Anti-TNFα Agents: Abstract P57 Table 1
  109. Weight loss and lumbosacral back pain in a 79-year-old Indian man
  110. Malignant mimicry—a 17-year-old with abdominal pain and weight loss
  111. PTU-113 Quality of life in patients with ileoanal pouch: a survey comparing two different patient populations
  112. PTU-096 The use of commercial interferon-γ release assays to screen for mycobacterial infection in inflammatory bowel disease patients initiating anti-TNF agents
  113. Irritable bowel syndrome
  114. Influence of smoking and other environmental factors in inflammatory bowel disease activity: what do our patients think?
  115. Iron deficiency anaemia is common in patients with an ileoanal pouch and is not always associated with inflammation
  116. There will be blood... a complete audit cycle
  117. Images of the terminal ileum are more convincing than cecal images for verifying the extent of colonoscopy
  118. Attitudes and Experiences of Adolescents in an Innovative IBD Transition Service
  119. Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome
  120. The effect of Khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion
  121. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease
  122. Gastrointestinal Manifestations of Systemic Sclerosis
  123. Pharmacological modulation of gut mucosal and large vessel blood flow
  124. Reaping value from intellectual property: DuPont's strategic approach achieves global growth
  125. Ghrelin augments afferent response to distension in rat isolated jejunum
  126. The effect of different macronutrient infusions on appetite, ghrelin and peptide YY in parenterally fed patients
  127. Diabetes and the Gastrointestinal System
  128. Prokineticin-2, motilin, ghrelin and metoclopramide: Prokinetic utility in mouse stomach and colon
  129. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study
  130. Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome
  131. Sporadic duodenal adenoma is associated with colorectal neoplasia
  132. Ghrelin for the gastroenterologist: history and potential
  133. Biofeedback, not laxatives, improves symptoms, transit and autonomic tone in functional constipation
  134. Medical management of diverticular disease
  135. Colonic Disorders